Biomarkers for Allogeneic HCT Outcomes

Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) eff...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2020-04, Vol.11, p.673-673
Main Authors: Adom, Djamilatou, Rowan, Courtney, Adeniyan, Titilayo, Yang, Jinfeng, Paczesny, Sophie
Format: Article
Language:English
Subjects:
Animals
biomarkers
Biomarkers - blood
Graft vs Host Disease - blood
Graft vs Tumor Effect
graft-versus-host disease
graft-versus-tumor
Hematologic Neoplasms - therapy
hematopoietic cell transplantation
Hematopoietic Stem Cell Transplantation - methods
Humans
Immunology
Prognosis
proteomics
Transplantation, Homologous - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) effect. Over the last decade, advances in "omics" technologies and systems biology analysis, have allowed for the discovery and validation of blood biomarkers that can be used as diagnostic test and prognostic test (that risk-stratify patients before disease occurrence) for acute and chronic GVHD and recently GVT. There are also predictive biomarkers that categorize patients based on their likely to respond to therapy. Newer mathematical analysis such as machine learning is able to identify different predictors of GVHD using clinical characteristics pre-transplant and possibly in the future combined with other biomarkers. Biomarkers are not only useful to identify patients with higher risk of disease progression, but also help guide treatment decisions and/or provide a basis for specific therapeutic interventions. This review summarizes biomarkers definition, omics technologies, acute, chronic GVHD and GVT biomarkers currently used in clinic or with potential as targets for existing or new drugs focusing on novel published work.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.00673